| Previous Close | 22.05 |
| Open | 22.00 |
| Bid | 21.56 x 1000 |
| Ask | 21.92 x 1000 |
| Day's Range | 21.22 - 22.44 |
| 52 Week Range | 16.95 - 29.00 |
| Volume | 41,643 |
| Avg. Volume | 175,037 |
| Market Cap | 509.228M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1,760.32 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.25 |
BOSTON-- -- Completed multiple financings in 2019, including initial public offering, raising $184.7 million to fund clinical development of novel CNS pipeline Results from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track to report data in late 2019 Two programs to initiate clinical trials by the end of 2019, including programs for ...
Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present at the 2019 Wedbush PacGrow Healthcare Conference at 9:45 a.m.
President & CEO of Karuna Therapeutics Inc (NASDAQ:KRTX) Steven M Paul bought 10,000 shares of KRTX on 06/28/2019 at an average price of $23.04 a share.
Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the closing of its initial public offering of 6,414,842 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 836,718 additional shares of common stock, at a public offering ...
Karuna Therapeutics, Inc. (NASDAQ: KRTX ) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Karuna focuses on developing novel therapies to address disabling ...
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the pricing of its upsized initial public offering of 5,578,124 shares of common stock at a public offering price of $16.00 per share. In addition, Karuna has granted the underwriters a 30-day option to purchase up to 836,718 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week. The IPO Terms Boston, Massachusetts-based Karuna Therapeutics, ...